Evidence map›Paper›PMID 30549400›Full record

ArticleCytometry. Part A : the journal of the International Society for Analytical Cytology2018

An integrated enrichment system to facilitate isolation and molecular characterization of single cancer cells from whole blood.

Liping Yu, Silin Sa, Ling Wang, Keely Dulmage, Neha Bhagwat, Stephanie S Yee, Moen Sen, Charles H Pletcher, Jonni S Moore, Suraj Saksena and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Cell Separations and Sorting.Analytical chemistry · 2020
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Liping YuBD Biosciences, San Jose, California.
Silin SaBD Biosciences, San Jose, California.
Ling WangBD Technologies and Innovation, Durham, North Carolina.
Keely DulmageBD Technologies and Innovation, Durham, North Carolina.
Neha BhagwatDivision of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Stephanie S YeeDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Moen SenDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Charles H PletcherDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Jonni S MooreDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Suraj SaksenaBD Biosciences, San Jose, California.
Eric P DixonBD Technologies and Innovation, Durham, North Carolina.
Erica L CarpenterDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
University of Pennsylvania · USBD Biosciences (United States) · USBD Technologie (United States) · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3M
Real-time monitoring of circulating pancreatic tumor cells and clustersR01CA207643 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARPENTER, ERICA · 2016 to 2021
$2.3M
NCI NIH HHS R01 CA207643
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) carry valuable biological information. While enumeration of CTCs in peripheral blood is an FDA-approved prognostic indicator of survival in metastatic prostate and other cancers, analysis of CTC phenotypic and genomic markers is needed to identify cancer origin and elucidate pathways that can guide therapeutic selection for personalized medicine. Given the emergence of single-cell mRNA sequencing technologies, a method is needed to isolate CTCs with high sensitivity and specificity as well as compatibility with downstream genomic analysis. Flow cytometry is a powerful tool to analyze and sort single cells, but pre-enrichment is required prior to flow sorting for efficient isolation of CTCs due to the extreme low frequency of CTCs in blood (one in billions of blood cells). While current enrichment technologies often require many steps and result in poor recovery, we demonstrate a magnetic separator and acoustic microfluidic focusing chip integrated system that enriches rare cells in-line with FACS™ (fluorescent activated cell sorting) and single-cell sequencing. This system analyzes, isolates, and index sorts single cells directly into 96-well plates containing reagents for Molecular Indexing (MI) and transcriptional profiling of single cells. With an optimized workflow using the integrated enrichment-FACS system, we performed a proof-of-concept experiment with spiked prostate cancer cells in peripheral blood and achieved: (i) a rapid one-step process to isolate rare cancer cells from lysed whole blood; (ii) an average of 92% post-enrichment cancer cell recovery (R

Indexed as

Cell CountCell Line, TumorCell SeparationFlow CytometryHumansNeoplasmsNeoplastic Cells, CirculatingSingle-Cell Analysiscell sortingCTCin-line enrichmentsingle cell RNA sequencing

Identifiers

PMID30549400
PMCPMC8176865
OpenAlexW2905080612

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.